Rheumatoid Arthritis Disease length
Item
have a diagnosis of ra for at least 3 months prior to screening
boolean
C0003873 (UMLS CUI [1,1])
C0872146 (UMLS CUI [1,2])
Latent Tuberculosis Absent | Tuberculosis Absent | Tuberculosis test negative
Item
have no history of latent or active tuberculosis (tb) and test negative for tb
boolean
C1609538 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
C0041296 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
C2242735 (UMLS CUI [3])
Inflammatory disorder | Exception Rheumatoid Arthritis
Item
have inflammatory diseases other than ra
boolean
C1290884 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0003873 (UMLS CUI [2,2])
Antirheumatic Drugs, Disease-Modifying | Immunosuppressive Agents Systemic | Exception Methotrexate | Exception Sulfasalazine | Exception Hydroxychloroquine
Item
have been treated with disease-modifying anti-rheumatic drugs (dmards)/systemic immunosuppressives other than methotrexate (mtx), sulfasalazine, or hydroxychloroquine during the 4 weeks prior to the first administration of study agent
boolean
C0242708 (UMLS CUI [1])
C0021081 (UMLS CUI [2,1])
C0205373 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0025677 (UMLS CUI [3,2])
C1705847 (UMLS CUI [4,1])
C0036078 (UMLS CUI [4,2])
C1705847 (UMLS CUI [5,1])
C0020336 (UMLS CUI [5,2])
Adrenal Cortex Hormones Intramuscular | Adrenal Cortex Hormones Intravenous | Intraarticular injection of corticosteroids
Item
have received intramuscular (im), iv, or intra-articular corticosteroids within 4 weeks of study agent administration
boolean
C0001617 (UMLS CUI [1,1])
C1556154 (UMLS CUI [1,2])
C0001617 (UMLS CUI [2,1])
C1522726 (UMLS CUI [2,2])
C2064783 (UMLS CUI [3])
Human immunoglobulin allergy
Item
have a known hypersensitivity to human ig proteins
boolean
C0571543 (UMLS CUI [1])
infliximab | golimumab | adalimumab | abatacept | Etanercept | anakinra
Item
have received infliximab, golimumab, adalimumab or abatacept within 3 months, or etanercept or anakinra within 1 month prior to the first administration of study agent
boolean
C0666743 (UMLS CUI [1])
C2353893 (UMLS CUI [2])
C1122087 (UMLS CUI [3])
C1619966 (UMLS CUI [4])
C0717758 (UMLS CUI [5])
C0245109 (UMLS CUI [6])
alefacept | efalizumab | natalizumab | rituximab | B-cell depletion therapy
Item
have received alefacept, efalizumab, natalizumab, rituximab, or any b-cell-depleting agent
boolean
C0962603 (UMLS CUI [1])
C1174995 (UMLS CUI [2])
C1172734 (UMLS CUI [3])
C0393022 (UMLS CUI [4])
C1171324 (UMLS CUI [5])
Biological agents | Investigational New Drugs
Item
have been treated with any other biologics or investigational drugs, within 5 half-lives of that drug prior to the first administration of study agent
boolean
C0005515 (UMLS CUI [1])
C0013230 (UMLS CUI [2])
Granulomatous infection Latent | Granulomatous infection | Tuberculosis | Histoplasmosis | Coccidioidomycosis
Item
have a history of latent or active granulomatous infection, including tuberculosis (tb), histoplasmosis, or coccidioidomycosis, prior to screening
boolean
C1610637 (UMLS CUI [1,1])
C0205275 (UMLS CUI [1,2])
C1610637 (UMLS CUI [2])
C0041296 (UMLS CUI [3])
C0019655 (UMLS CUI [4])
C0009186 (UMLS CUI [5])
Bacillus Calmette-Guerin vaccination
Item
have had a bacille calmette-guerin (bcg) vaccination within 12 months of screening
boolean
C4305105 (UMLS CUI [1])
Communicable Disease Serious | Hepatitis | Pneumonia | Pyelonephritis | Sepsis
Item
have had a serious infection (eg, hepatitis, pneumonia, pyelonephritis, or sepsis)
boolean
C0009450 (UMLS CUI [1,1])
C0205404 (UMLS CUI [1,2])
C0019158 (UMLS CUI [2])
C0032285 (UMLS CUI [3])
C0034186 (UMLS CUI [4])
C0243026 (UMLS CUI [5])